Back

The effect of trimetazidine in heart failure on clinical endpoints: a systematic review

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pathophysiology and mechanisms 13 Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Mr Soufiane Nassiri

Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Development of an Advanced Nurse Practitioner Led clinic to enhance access to heart failure diagnosis and treatment
Ms N. Caples (Waterford, IE)
Abstract Slides Video
Presentation thumbnail
Acceptance, use and effect of a mobile application for heart failure patients. A pilot study
Associate Professor F. Schoenrath (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
How can we increase adherence to medical treatment in heart failure patients? A questionnaire study
Assistant Professor A. Sahin (Canakkale, TR)
Abstract Slides Video
Presentation thumbnail
Characterization of dilated cardiomyopathy patients with persistently reduced ejection fraction
Doctor I. Gomes Campos (Penafiel, PT)
Abstract Slides Video
Presentation thumbnail
Impact of optimal guideline-directed medical therapy on morbidity and mortality in patients with severely reduced ejection fraction from chronic aortic regurgitation undergoing aortic valve surgery
Doctor A. Cinq-Mars (Paris, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - pathophysiology and mechanisms 13

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Metabolic intervention with trimetazidine improves intracardiac hemodynamics in patients with advanced heart failure
thumbnail
Congress Presentation
Pharmacological treatments in adults with chronic heart failure: a systematic review and component network meta-analysis
thumbnail
Congress Presentation
Safety and use de trimetazidine in Cancer Therapy-Related Cardiac Dysfunction (CTRCD) secondary to breast cancer for LVEF recovery.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources